Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. New emerging areas of research have been proposed to play key roles in the development of mucositis, providing rationale for potential new therapeutics for the prevention, treatment or management of chemotherapy-induced mucositis. This review aims to address these new areas of research and to comment on the therapeutics arising from them.
Keywords: Analgesics; Antimicrobials; Antioxidants; Benzydamine hydrochloride (HCl); Cancer side effects; Chemotherapy-induced gut toxicity; Coating agents; Mucositis; Mucositis treatment; Palifermin; Probiotics; R-spondin1; Toxicity; Zinc sulphate.